Roivant Sciences (ROIV) news
Recent news
Roivant continues to own 19.5% Arbutus stake after tender offer
AInvest Wire · Oct 6, 2026Arbutus: Roivant Sciences to maintain ~19.5% stake after offer
AInvest Wire · Sep 30, 2026Roivant Sciences shares down 1.4% premarket; co announces topline results from proof-of-concept study of imvt-1402 in cutaneous lupus erythematosus
Roivant Sciences Ltd. shares were down 1.4% in premarket trading on September 23, 2026, following the company’s announcement of topline results from a proof-of-concept study of its investigational drug Imvt-1402 in patients with cutaneous lupus erythematosus [1]. The study aimed to evaluate the…
AInvest Wire · Sep 23, 2026Roivant announces topline results from proof-of-concept study
Roivant Sciences has announced topline results from a proof-of-concept study evaluating its experimental drug for a type of pulmonary hypertension. The drug, mosliciguat, achieved its primary endpoint, demonstrating a statistically significant 56% reduction in pulmonary vascular resistance compared…
AInvest Wire · Sep 23, 2026Roivant Sciences Ltd: Stifel initiates coverage with buy rating; target price $51
AInvest Wire · Sep 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.